Skip to main content

Lorena Ramos Pérez

Institutions of which they are part

Research technician
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Lorena Ramos Pérez

Institutions of which they are part

Research technician
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Mecanismos moleculares que regulan la sex hormone- binding globulin y sus implicaciones terapéuticas.

IP: David Martinez Selva
Collaborators: Lidia Fuertes Rioja, Maria Teresa Salcedo Allende, Lorena Ramos Pérez, Pablo Gabriel Medina
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI18/00320
Duration: 01/01/2019 - 31/12/2022

Función de la Sex Hormone-Binding Globulin en el Tejido Adiposo: Caracterización de la Expresión, Regulación e Implicaciones Terapéuticas.

IP: David Martinez Selva
Collaborators: Jose Manuel Fort López-Barajas, Lorena Ramos Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 177265
Reference: PI15/00823
Duration: 01/01/2016 - 30/09/2019

Diabetis i Metabolisme (GRC)

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Andreea Ciudin Mihai, Lorena Ramos Pérez, Rosa Burgos Peláez, Olga Simó Servat, Patricia Bogdanov Baruj
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2014 SGR 270
Duration: 01/01/2014 - 31/12/2016

Mecanismos moleculares que regulan la expresión de la SHBG en la obesidad y en la distribución de la grasa corporal inducida por la dieta: implicaciones terapéuticas

IP: David Martinez Selva
Collaborators: M Luisa Chicharro Serrano, Andreea Ciudin Mihai, Lorena Ramos Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 183315
Reference: PI12/01357
Duration: 01/01/2013 - 31/12/2015

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Andrea Casal Pardo

Andrea Casal Pardo

Predoctoral researcher
Kidney Physiopathology
Read more
Rosa Casado Fernández

Rosa Casado Fernández

Main researcher
Multidisciplinary Nursing Research Group
Read more
Telma Segura Rovira

Telma Segura Rovira

P Management and Admin. Project manager
Talent Attraction and Acquisition Unit
Human Resources Directorate
Read more
Mª Jose Jurado Luque

Mª Jose Jurado Luque

Predoctoral researcher
Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.